• US: +1 9176726599
  • Login

Recombinant Human EGF Market by Product Type (Amphiregulin, Betacellulin, Epigen, Heparin Binding-EGF, Neuregulins, Transforming Growth Factor-α, Others), by Purity (98% SDS-PAGE, 95%-98% SDS-PAGE, <95% SDS-PAGE), by Carrier Type (Carrier Protein and Carrier Free), by Formulation (Liquid, Lyophilized Powder, Others), by Application (Brain Tumor Therapy, Gastrointestinal Ulceration, Wound Healing, Others) and Region Outlook 2021 - 2027

Format: PDF | Pages: 314 | Report ID: MRS1105


Report Description

The global Recombinant Human EGF Market size is estimated at USD 10,804.1 Million in 2020, expanding at a CAGR of 9.2% from 2021-2027 to reach 18,800.7 Million USD in 2027.

Market Dynamics

Stevens-Johnson syndrome, bedsores, scalds, diabetic foot ulcers, and other patients with chronic wounds could be efficiently treated using recombinant EGF. Within the cosmetics business, rhEGF is used to improve skin texture, reduce hyperpigmentation, reduce scar development, and among other things. Furthermore, rhEGF may be utilized to make synthesized culture media, which is employed in bioengineering to create artificial organs. Furthermore, recombinant human EGF can be utilized to cure eye injury by encouraging the development and repair of epidermal cells in the eyes.

Over the projected period, increased incidences of acute wounds, corneal damage, chronic wounds, and other conditions are likely to fuel the expansion of the recombinant human EGF market. For example, according to research issued by Ecronicon in May 2020, the frequency of foot ulcers was 4-10 percent worldwide, and wound treatments accounted for 17.2 million hospital stays every year on average.

Furthermore, the growing investments in r&d aimed at determining the numerous applications of recombinant human EGF are likely to boost the market's growth during the forecast period. In July 2020, according to a report released by NCBI, Luoyang Normal University and Ocean University of China established a novel delivery mechanism for recombinant EGF delivery to the wound site utilizing nanoparticles. This new approach aids in enhancing EGF bioavailability at the wound site as well as ensuring its long-term release.

Regional Insights

North America is likely to have a substantial position in the market during the forecast period, owing to the increased rates of diabetes. According to the Prevention's National Diabetes and Centers for Disease Control Statistics Report-2020, approximately 34.2 million persons in the United States have diabetes, and 34.5 percent of the population is borderline diabetic. As rhEGFs are widely utilized for the prevention of diabetic ulcers, this is predicted to promote the future growth of recombinant human EGFs.

Product type, purity, formulation, and application are the three segments that make up the recombinant human EGF market. Due to the rising occurrence of chronic wounds throughout the world, the wound heading segment is likely to account for a considerable market share.

Competitive Insights

Major companies in the industry participate in strategic acquisitions and mergers, alliances, and new product releases to stay competitive in the market. In 2019, Uni-Bio Science Group Limited, a China pharmaceutical business, established cooperation with Medlink, a software solution provider based in the U.K., to support the sale of GeneTime, a recombinant human EGF-based medication for ulcer therapy.

The report begins with an overview of the Industry Chain structure, and describes the industry environment, then analyses market size and forecast of Recombinant Human EGF Market by product type, purity, carrier types, formulation, application, and region. In addition, this report introduces the market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):

  • Abcam PLC
  • BioLegend, Inc.
  • BioVision, Inc.
  • Cell Guidance Systems Ltd.
  • Cell Sciences, Inc.
  • Creative BioMart
  • EnQuire BioReagents
  • Eurofins DiscoverX
  • FUJIFILM Irvine Scientific, Inc.
  • Miltenyi Biotec
  • PeproTech, Inc.
  • Prospec-Tany TechnoGene Ltd
  • R&D Systems
  • RayBiotech, Inc.
  • ScienCell Research Laboratories
  • Sino Biological Inc.
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific
  • Tonbo Biosciences

Product Type Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • Amphiregulin
  • Betacellulin
  • Epigen
  • Heparin Binding-EGF
  • Neuregulins
  • Transforming Growth Factor-α
  • Others

Purity Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • 98% SDS-PAGE
  • 95%-98% SDS-PAGE
  • <95% SDS-PAGE

Carrier Type Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • Carrier Protein
  • Carrier Free

Formulation Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • Liquid
  • Lyophilized Powder
  • Others

Application Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • Brain Tumor Therapy
  • Gastrointestinal Ulceration
  • Wound Healing
  • Others

Region Coverage (Regional Consumption, Demand & Forecast by Countries, etc.):

  • North America (U.S., and Canada)
  • Europe (Germany, U.K., France, Italy, Spain, etc.)
  • Asia-Pacific (China, India, Japan, Indonesia, Malaysia, Australia, South Korea, etc.)
  • South America (Brazil, Mexico, Argentina, etc.)
  • Middle East & Africa (Saudi Arabia, Kuwait, UAE, South Africa, etc.) 

Frequently Asked Questions

The global Recombinant Human EGF Market size is estimated at USD 10,804.1 Million in 2020, expanding at a CAGR of 9.2% from 2021-2027 to reach 18,800.7 Million USD in 2027.
North America captured the highest revenue in 2021 and is projected to continue its dominance during the study period.
The global Recombinant Human EGF Market size is expanding at a CAGR of 9.2% from 2021-2027 to reach 18,800.7 Million USD in 2027.
Asia Pacific (especially China, and India) region is projected to grow at the fastest growth rate during the study period.
Major companies in the industry participate in strategic acquisitions and mergers, alliances, and new product releases to stay competitive in the market. In 2019, Uni-Bio Science Group Limited, a China pharmaceutical business, established cooperation with Medlink, a software solution provider based in the U.K., to support the sale of GeneTime, a recombinant human EGF-based medication for ulcer therapy.

Why Choose Market Research Strategy?

  Authenticated Data Sources

We utilize market analysis/information from verified authenticated data sources to scoop accurate research reports

  Express Delivery

We understand the urgency of our clients and their clients' in the competitive space thus, deliver the report in minimum turnaround

  Gain Instant Access

Without further ado, choose us and get instant access to reliable analysis to help you make the right business decisions.

  Our Pledge to You

We abide by the information security policy and adheres to keep your private and business information confidential and secure.

Copyright © 2022 Market Research Strategy, All rights reserved.